- Home
- ORKA vs OPK Comparison
ORKA vs OPK Comparison
Compare ORKA & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKA
- OPK
- Stock Information
- Founded
- ORKA 2004
- OPK 2007
- Country
- ORKA United States
- OPK United States
- Employees
- ORKA N/A
- OPK N/A
- Industry
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- OPK Biotechnology: Pharmaceutical Preparations
- Sector
- ORKA Health Care
- OPK Health Care
- Exchange
- ORKA Nasdaq
- OPK Nasdaq
- Market Cap
- ORKA 1.0B
- OPK 1.1B
- IPO Year
- ORKA N/A
- OPK 1995
- Fundamental
- Price
- ORKA $19.97
- OPK $1.45
- Analyst Decision
- ORKA Strong Buy
- OPK Strong Buy
- Analyst Count
- ORKA 6
- OPK 3
- Target Price
- ORKA $43.60
- OPK $2.75
- AVG Volume (30 Days)
- ORKA 394.7K
- OPK 3.3M
- Earning Date
- ORKA 02-15-2025
- OPK 02-25-2025
- Dividend Yield
- ORKA N/A
- OPK N/A
- EPS Growth
- ORKA N/A
- OPK N/A
- EPS
- ORKA N/A
- OPK N/A
- Revenue
- ORKA N/A
- OPK $711,408,000.00
- Revenue This Year
- ORKA N/A
- OPK N/A
- Revenue Next Year
- ORKA N/A
- OPK $0.00
- P/E Ratio
- ORKA N/A
- OPK N/A
- Revenue Growth
- ORKA N/A
- OPK N/A
- 52 Week Low
- ORKA $17.64
- OPK $0.85
- 52 Week High
- ORKA $53.88
- OPK $1.76
- Technical
- Relative Strength Index (RSI)
- ORKA N/A
- OPK 34.57
- Support Level
- ORKA N/A
- OPK $1.43
- Resistance Level
- ORKA N/A
- OPK $1.54
- Average True Range (ATR)
- ORKA 0.00
- OPK 0.07
- MACD
- ORKA 0.00
- OPK -0.01
- Stochastic Oscillator
- ORKA 0.00
- OPK 6.06
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. It is to offer patients suffering from chronic skin diseases like plaque psoriasis.
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.